Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Emyria Ltd ( (AU:EMD) ) just unveiled an announcement.
Emyria Limited has announced a multi-year agreement with Medibank, Australia’s largest private health insurer, to fund Emyria’s PTSD care program at Perth Clinic. This partnership marks the first major private health insurance funding for a psychotherapy-led PTSD program in Australia, validating Emyria’s Empax Model. The program, which integrates psychiatrist-supervised therapy and real-world data capture, is now accessible to eligible Medibank customers without out-of-pocket costs. This collaboration positions Emyria as a national leader in mental health care and supports its expansion strategy to establish additional centers and partnerships across Australia. The program’s outcomes will be independently evaluated by the Australian National University to support broader adoption and reimbursement.
More about Emyria Ltd
Emyria Limited is a leader in developing and delivering innovative mental health treatments, focusing on advanced psychological trauma care. The company aims to scale a sustainable, data-generating mental health platform nationally.
Average Trading Volume: 418,404
Technical Sentiment Signal: Sell
Current Market Cap: A$12.28M
For detailed information about EMD stock, go to TipRanks’ Stock Analysis page.